Recruitment status changed
Before: Active not recruiting. After: Terminated.
Among the trials TrialRedline tracks, 56 changed their ClinicalTrials.gov record in November 2026 so far: 7 status changes to terminated, withdrawn or suspended, 7 primary outcome text edits, 9 completion dates moved later, 2 completion dates moved earlier, 15 enrollment changes, 20 other status changes. Each entry shows the previous and updated value and links to the registry's own version comparison.
7 in November 2026. Recruitment status changed to Terminated, Withdrawn or Suspended. Terminated first, then newest.
Before: Active not recruiting. After: Terminated.
Before: Active not recruiting. After: Terminated.
Before: Active not recruiting. After: Terminated.
Before: Active not recruiting. After: Terminated.
Before: Active not recruiting. After: Terminated.
Before: Recruiting. After: Terminated.
Before: Not yet recruiting. After: Withdrawn.
7 in November 2026. The text of the main study measures changed. Edits to capitalization, punctuation or spacing alone are left out. Newest first.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) Time frame: Through 24 months. After: Measure: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Description: An adverse event (AE) was defined as any untoward medical occurrence that developed or worsened in severity during the conduct of a clinical study and did not necessarily have a causal relationship to study drug. TEAEs were defined as AEs that started on or after the first dose date of study drug. A summary of all Serious Adverse Events (SAEs) and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section. Time frame: Baseline through Month 24.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Evaluate the safety and tolerability of ADX-038 Description: Incidence and severity of TEAEs Time frame: Length of study - 36 months. After: Measure: Evaluate the safety and tolerability of ADX-038 Description: Incidence and severity of TEAEs Time frame: Length of study - From Day 1 through Month 24.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: 28-day all-cause mortality rate Description: Proportion of participants who die from any cause by Day 28 after the first dose of study treatment. Time frame: From Day 1 (first NAI dose) through Day 28. After: Measure: 28-day all-cause mortality rate Description: Proportion of participants who die from any cause by Day 28 after the first dose of study treatment. Time frame: From Day 1 (first dose of study treatment) through Day 28.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Progression free survival (PFS) Description: PFS is defined as the time from randomization until disease progression or death from any cause, whichever occurs first. Progression is per response evaluation criteria in solid tumors (RECIST) v1.1 and as assessed by Investigator. Time frame: Up to approximately 2 years Measure: Overall survival (OS) Description: OS is defined as the time from randomization until death from any cause. Time frame: Up to approximately 2 years. After: Measure: Progression free survival (PFS) as assessed by blinded independent central review (BICR) Description: Comparison of PFS of daraxonrasib + gemcitabine and nab-paclitaxel (Arm B) versus gemcitabine and nab-paclitaxel (Arm C). PFS is defined as the time from randomization until disease progression or death from any cause, whichever occurs first. Progression is per response evaluation criteria in solid tumors (RECIST) v1.1 and as assessed by BICR. Time frame: Up to approximately 2 years Measure: Overall survival (OS) Description: Comparison of OS of daraxonrasib + gemcitabine and nab-paclitaxel (Arm B) versus gemcitabine and nab-paclitaxel (Arm C). OS is defined as the time from randomization until death from any cause. Time frame: Up to approximately 2 years.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Difference in mean change in body weight in patients treated with setmelanotide compared to placebo, assessed as percent change in BMI Time frame: Baseline to 52 weeks. After: Measure: Treatment Period: Percent Change From Baseline in Body Mass Index (BMI) Description: BMI was calculated using participant's weight and height assessments as weight in kilograms (kg)/(height in meters \[m\])\^2. Baseline was defined as the last available measurement taken prior to the start of treatment administration. An analysis of covariance (ANCOVA) model was used to calculate the least-squares mean with randomization stratification factors and baseline value as a covariate. Time frame: Baseline, Week 52.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Adverse Event (AE) Query Description: Incidence and severity of AEs Time frame: From Day 1 to Day 90. After: Measure: Number of Subjects With Serious Adverse Events Description: The proportion of subjects that experience at least one serious adverse event Time frame: The safety assessment period was approximately 15 weeks..
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Best Overall Response Description: Percentage of patients whose Best Overall Response (BOR) is assessed as Complete Response (CR) or Partial Response (PR) as assessed by RECIST 1.1 Time frame: From randomization to treatment discontinuation for any reason, average 6 months. After: Measure: Best Overall Response Description: Percentage of patients whose Best Overall Response (BOR) is assessed as Complete Response (CR) or Partial Response (PR). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT or MRI: CR: disappearance of all target lesions; PR: \>=30% decrease in the sum of the longest diameter of target lesions. Time frame: From randomization to treatment discontinuation for any reason, average 6 months.
9 in November 2026. Primary completion date moved later while its type (estimated or actual) stayed the same. Largest move first.
Before: 31 Jan 2028. After: 4 Aug 2029.
Before: 31 Dec 2028. After: 30 Apr 2030.
Before: Sep 2026. After: Dec 2027.
Before: Nov 2026. After: Mar 2029.
Before: Sep 2026. After: Dec 2026.
Before: Dec 2026. After: Dec 2029.
Before: Aug 2026. After: Dec 2027.
Before: Nov 2026. After: 16 Apr 2027.
Before: Feb 2027. After: Jul 2027.
2 in November 2026. Primary completion date moved earlier while its type stayed the same. Largest move first.
Before: 22 Dec 2025. After: 19 Dec 2025.
Before: Jun 2028. After: Apr 2028.
15 in November 2026. The participant count changed. Planned and actual counts are shown as recorded. Newest first.
Before: 760 participants (planned). After: 861 participants (actual).
Before: 244 participants (planned). After: 279 participants (actual).
Before: 45 participants (planned). After: 85 participants (planned).
Before: 450 participants (planned). After: 357 participants (actual).
Before: 50 participants (planned). After: 0 participants (actual).
Before: 20 participants (planned). After: 5 participants (actual).
Before: 90 participants (planned). After: 93 participants (actual).
Before: 600 participants (planned). After: 900 participants (planned).
Before: 60 participants (planned). After: 67 participants (actual).
Before: 675 participants (planned). After: 667 participants (actual).
Before: 60 participants (planned). After: 61 participants (actual).
Before: 60 participants (planned). After: 55 participants (actual).
Before: 255 participants (planned). After: 66 participants (actual).
Before: 510 participants (planned). After: 570 participants (planned).
Before: 20 participants (planned). After: 3 participants (actual).
20 in November 2026. Any other change of recruitment status, such as recruiting to completed. Newest first.
Before: Enrolling by invitation. After: Recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Active not recruiting. After: Completed.
Before: Active not recruiting. After: Completed.
Before: Active not recruiting. After: Completed.
Before: Recruiting. After: Completed.
Before: Active not recruiting. After: Completed.
Before: Not yet recruiting. After: Recruiting.
Before: Active not recruiting. After: Completed.
Before: Not yet recruiting. After: Recruiting.
Before: Recruiting. After: Completed.
Before: Recruiting. After: Active not recruiting.
Before: Recruiting. After: Active not recruiting.
Before: Active not recruiting. After: Completed.
Before: Recruiting. After: Completed.
Before: Active not recruiting. After: Completed.
Before: Not yet recruiting. After: Recruiting.
Before: Active not recruiting. After: Completed.
TrialRedline, “Clinical trial registry changes: November 2026”. https://trialredline.com/reports/2026-11
Based on public ClinicalTrials.gov record history. How we collect and check the data